Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of SHP626 in Overweight and Obese Adults
NCT02287779Phase 1Completed
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Jan 2015
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing SHP626 with Placebo (2 arms). Primary endpoints: Number of Participants With Treatment-emergent Adverse Events Related to Standard Hematology, Number of Participants With Treatment-emergent Adverse Events Related to Fat Soluble Vitamins and 9 more. Started Jan 2015; status: completed.
02
Drugs
volixibat
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02287779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02287779.